光子联合碳离子放射治疗鼻窦恶性肿瘤:HIT-SNT前瞻性2期试验结果
这项前瞻性2期HIT-SNT试验于2011至2019年纳入35例组织学证实、不完全切除或不可手术的鼻窦腺癌(51%)或鳞状细胞癌(49%)患者,采用IMRT 50 Gy联合碳离子推量24 Gy(相对生物效应)至总剂量74 Gy。2年总生存率79.4%、局部无进展生存率61.8%、无进展生存率61.8%、无转移生存率64.8%。
要点
- 急性黏膜炎CTCAE 3级发生于12%(n=4)患者,伴吞咽痛CTCAE 3级。
- 除1例3级体重下降外,未见其他急性3-4级毒性。
- 15例可长期随访患者放疗后2年未见≥3级远期副作用。
核心结论
- 据作者所知,这是鼻窦恶性肿瘤这一罕见病种双模态放疗毒性与结局的首个前瞻性数据。
- 研究显示双模态放疗后CTCAE报告的急性毒性发生率低,肿瘤控制和生存率合理,因此该治疗方法仍需进一步评估。
研究设计与样本
- 前瞻性2期IMRT-Heidelberg Ion-Beam Therapy Sinonasal Tumors(HIT-SNT)试验。
- 2011至2019年治疗35例组织学证实、不完全切除或不可手术的鼻窦腺癌(51%)或鳞状细胞癌(49%)患者。
- 治疗方案为IMRT 50 Gy联合碳离子推量24 Gy(相对生物效应),总剂量74 Gy。
主要发现
- 急性黏膜炎CTCAE 3级发生于12%的患者(n=4),并伴有吞咽痛CTCAE 3级。
- 除1例3级体重下降外,未观察到其他急性高级别毒性(3-4级)。
- 在15例符合长期随访条件的小队列患者中,放疗后2年未见高级别(≥3级)远期副作用。
- 这些患者均未出现治疗相关的视力或听力丧失。
- 2年总生存率为79.4%,2年局部无进展生存率为61.8%,2年无进展生存率为61.8%,2年无转移生存率为64.8%。
局限性
- 长期随访仅基于15例符合条件的小队列患者。
- 作者结论指出该治疗方法仍需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation treatment of sinonasal malignancies is a challenging task due to proximity to critical structures of the head and neck and skull base. Local tumor control is highly dose-dependent, but dose application is limited due to accompanying toxicity and dose constraints. To evaluate the toxicity and efficacy of combined radiation treatment with intensity-modulated radiation therapy (IMRT) and carbon ion boost, we conducted a prospective phase 2 IMRT-Heidelberg Ion-Beam Therapy Sinonasal Tumors (HIT-SNT) trial. METHODS AND MATERIALS: Between 2011 and 2019, we treated 35 patients with histologically proven, incompletely resected or inoperable adeno- (51%) or squamous cell carcinoma (49%) of the paranasal sinuses with combined IMRT (50 Gy) and carbon ion boost (24 Gy relative biologic effectiveness) to a total dose of 74 Gy. RESULTS: Acute mucositis Common Terminology Criteria for Adverse Events (CTCAE) grade 3 occurred in 12% of patients (n = 4) and was accompanied by odynophagia CTCAE grade 3. Except for 1 case of grade 3 weight loss, no other acute high-grade toxicity (grade 3-4) was observed. In a small patient cohort of 15 patients eligible for long-term follow-up we have seen no high-grade (grade ≥3) long-term side effects 2 years after radiation therapy. None of these patients suffered from therapy-associated vision or hearing loss. Secondary endpoints were 2-year overall survival, 2-year local progression-free survival, 2-year progression-free survival, and 2-year metastases-free survival with 79.4%, 61.8%, 61.8%, and 64.8%, respectively. CONCLUSIONS: To our knowledge, this is the first prospective data on toxicity and outcome of bimodal radiation therapy for the rare entity of sinonasal malignancies. Our study shows a low rate of CTCAE-reported acute toxicity with reasonable tumor control and survival rates after bimodal radiation therapy, which therefore remains a therapy approach to be further evaluated.
引用
- Weusthof K, Held T, Lang K, et al. Combined Photon and Carbon Ion Radiation Therapy for Sinonasal Malignancies: Results of the HIT-SNT Prospective Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 37866761. doi:10.1016/j.ijrobp.2023.09.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。